本帖最后由 老马 于 2012-1-13 21:20 编辑
4 X) g9 g+ `/ h8 C" U/ t1 \9 W. X
/ X# T4 [4 h9 G1 E. X M- n _爱必妥和阿瓦斯丁的比较
- j6 v. x, Z- A8 g2 \
4 D* b. k- P8 o5 S
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
, e# ~! p( u- U' G9 `* ~2 M3 c( l- c% o* O
& `( ?) U5 n( I1 g
3 I0 j1 ~* E6 M) [% @( i2 Uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ t6 R+ {) N5 \/ ^6 o==================================================
2 P0 Z5 \/ k6 k9 B7 A$ T0 G5 FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 f- B: U+ S, p0 D& q+ M( n4 j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! U/ q/ i+ o0 X! Y. h4 b) Z3 [6 V: m
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% k' O0 u+ d7 l/ p) B
|